Scotiabank Raises AMGN Price Target to $500.00 Amid Optimism

Scotiabank analyst Louise Chen has maintained a 'Sector Outperform' rating on Amgen (AMGN) while increasing its price target to $500.00 from $450.00, reflecting optimism about the biotechnology company's future growth potential and market position.

This adjustment marks an 11.11% increase in the price target and follows mixed ratings from other analysts, indicating a somewhat divided sentiment in the market.

Amgen, one of the largest biotechnology companies globally, specializes in discovering, developing, and manufacturing biologic and small-molecule therapies for various diseases, including cancer and rare conditions.

The company's current price of $416.98 is 13.4% higher than its GF Value™ of $367.64, suggesting that investors may be paying a premium for the stock compared to its intrinsic value.